Alkermes 10-Q: Q3 Revenue Up 22% to $480M, but Nine-Month Swing to $49.7M Loss
ALKS sits 68% above its 52-week low of $27.
Summary
Alkermes' Q3 revenue rose 22% to $480.1M on LUMRYZ, but Avadel-related interest, amortization and inventory step-up pushed quarterly net income down to $16.3M and the nine-month result to a $49.7M loss.
Key Events · Earnings and Guidance · ALKS
-
Q3 Revenue Jumps 22% on LUMRYZ
Total revenues were $480.1M versus $394.2M a year ago, with LUMRYZ contributing $89.9M and product sales net of $417.3M.
-
Net Income Falls to $16.3M
Quarterly net income dropped from $82.8M to $16.3M ($0.09 diluted) as interest expense of $27.6M, intangible amortization of $19.7M and $28.7M of inventory step-up hit the P&L; the nine-month result was a $49.7M loss.
-
Avadel Deal Reshapes Balance Sheet
Total consideration was $2.31B, including $1.77B for the LUMRYZ intangible and $509.5M of goodwill, funded with $1.50B of term loans; cash and investments stood at $787.6M at September 30, 2026.
-
CVR Liability Rises on Higher Odds
The contingent consideration liability rose $27.0M in the nine months to $136.9M as the probability of achieving the CVR Milestone was raised from 75% to 90% after REVITALYZ; the maximum payout is $165.7M, expected to be determined by end-2027.
Analysis · ALKS · Life Sciences
The headline numbers were out hours earlier, so the surprise is gone — what is new here is the full GAAP picture behind them. Revenue of $480.1M rose 22% year over year, yet net income fell to $16.3M from $82.8M and the nine-month result swung to a $49.7M loss, because buying Avadel brought $27.6M of quarterly interest expense, $19.7M of intangible amortization and $28.7M of inventory step-up into cost of goods. LUMRYZ is already doing the work the deal was meant to do — $89.9M in the quarter and $226.0M since closing — and the CVR liability jumped $27.0M as management raised the odds of hitting the milestone from 75% to 90% after the REVITALYZ data. That is a paper remeasurement, not cash out the door, but it does mean a $165.7M payment becomes more likely by end-2027. With $787.6M of cash and investments against $1.50B of term loans, the balance sheet is levered but funded; the question for holders is how fast LUMRYZ and the orexin pipeline convert into the earnings the pre-deal business used to produce.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALKS was trading at $45.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $27.00 to $55.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.